<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396056</url>
  </required_header>
  <id_info>
    <org_study_id>StonyBrookU</org_study_id>
    <nct_id>NCT02396056</nct_id>
  </id_info>
  <brief_title>Enhancing Guided Bone Regeneration by Modifying a Resorbable Membrane</brief_title>
  <official_title>Enhanced Guided Bone Regeneration in Localized Osseous Alveolar Defects by Using a Novel Perforated Resorbable Barrier Membrane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Guided bone regeneration (GBR) procedures have significantly evolved over the last 20 years.&#xD;
      Significant advances have been made with various barrier membranes with or without the use of&#xD;
      bone grafts and other materials. Some of the main limitations of non-resorbable barriers&#xD;
      included cytotoxicity and need for removal, which can adversely affect the regenerated bone&#xD;
      volume. Similar GBR success has been documented extensively with cell occlusive resorbable&#xD;
      barriers membranes. Recently, the investigators demonstrated supracrestal bone regeneration&#xD;
      in guided tissue regeneration procedures in humans with the use of novel perforated barrier&#xD;
      membrane (MPM). The perforation allows mesenchymal stem cells and other progenitor cells&#xD;
      present in the gingival tissues to migrate into the osseous defect and contribute to the&#xD;
      osseous regeneration potential.&#xD;
&#xD;
      The objective of this study is to investigate the GBR potential of MPM in alveolar ridge&#xD;
      defects, relative to a similar occlusive barrier. Ten non-smoking patients that need&#xD;
      localized alveolar ridge augmentation prior to implant placement will be included into the&#xD;
      study. Patients will be divided into two groups, as follows: occlusive bovine collagen&#xD;
      membrane (OM control group, 5 patients) and modified bovine perforated collagen membrane (MPM&#xD;
      test group, 5 patients). All sites will be grafted with mineralized cortical bone allograft&#xD;
      and when needed cortical bone pins will be use for site stability. A Cone Bean (CT) will be&#xD;
      obtained prior to surgery and 6-8 months post treatment from which volumetric width changes&#xD;
      will be quantify. A bone biopsy will be obtained at the time of implant placement (~6-8&#xD;
      months) to determine residual graft particles and new bone formation. Dimensional width&#xD;
      changes will be assess at 6-8 months during re-entry for implant placement. Soft tissue&#xD;
      healing will be assessed at 2, 4, 8, 16 weeks and 6 months.&#xD;
&#xD;
      This study can potentially impact current bone augmentation techniques and may lead to the&#xD;
      modification of existing commercial membranes that will enhance site development prior to&#xD;
      implant placement. The contribution of progenitor cells to the osseous defect might lead to&#xD;
      greater bone formation and possible faster wound healing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical horizontal bone augmentation results through direct measurement.</measure>
    <time_frame>at 6 months post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volumetric measurements with CBCT</measure>
    <time_frame>pre- and 6 months post treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>De novo bone formation, and residual graft particles quantification with histomorphometric analysis</measure>
    <time_frame>at 6 months post treatment</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Alveolar Ridge Augmentation</condition>
  <arm_group>
    <arm_group_label>Occlusive Membrane (OM)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Five patients will be randomly assigned to the OM group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified Perforated Membrane (MPM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five patients will be randomly assigned to the MPM group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BioMend Extend</intervention_name>
    <description>Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.</description>
    <arm_group_label>Occlusive Membrane (OM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Modified BioMend Extend</intervention_name>
    <description>Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.</description>
    <arm_group_label>Modified Perforated Membrane (MPM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  at the augmentation site, the alveolar ridge must be deficient in a buccolingual&#xD;
             dimension (&lt; 5.5 mm): Class 1 Seibert defects.&#xD;
&#xD;
          -  alveolar ridges to be augmented must have a minimum of 4 mm of keratinized gingiva&#xD;
             extending the length of the planned augmentation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  general contraindications to implant surgery&#xD;
&#xD;
          -  subjected to irradiation, chemotherapy or immunosuppressive therapy over the past 5&#xD;
             years&#xD;
&#xD;
          -  poor oral hygiene and motivation&#xD;
&#xD;
          -  uncontrolled diabetes&#xD;
&#xD;
          -  pregnant or lactating&#xD;
&#xD;
          -  substance abusers&#xD;
&#xD;
          -  current smokers&#xD;
&#xD;
          -  psychiatric problems or unrealistic expectations&#xD;
&#xD;
          -  acute infection in the area intended for implant placement&#xD;
&#xD;
          -  positive to HIV and hepatitis B and C&#xD;
&#xD;
          -  affected by autoimmune diseases such as arthritis rheumatoid, systemic lupus&#xD;
             erythematosus, sclerodermia, Sjo Ìˆgren syndrome and dermatomyositis polymyositis&#xD;
&#xD;
          -  treated or under treatment with intravenous amino-bisphosphonates&#xD;
&#xD;
          -  subjected previously to reconstructive procedures of the posterior mandible and&#xD;
&#xD;
          -  under chronic treatment with steroids or non-steroidal anti-inflammatory drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julio A Carrion, DMD, PhD</last_name>
    <phone>631-632-9443</phone>
    <email>julio.carrion@stonybrook.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vincent J Iacono, DMD</last_name>
    <phone>631-632-8955</phone>
    <email>vincent.iacono@stonybrook.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>School of Dental Medicine of Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio A Carrion, DMD, PhD</last_name>
      <phone>631-632-9443</phone>
      <email>julio.carrion@stonybrook.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Guided Bone Regeneration</keyword>
  <keyword>Gingival Mesenchymal Stem Cells</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

